Clinical Trials
3545
534 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1849
Terminated
199
5.6%
Recruiting
645
18.2%
Suspended
10
0.3%
Withdrawn
93
2.6%
Active, not recruiting
106
3.0%
Unknown
416
11.7%
Completed
1648
46.5%
Enrolling By Invitation
2
0.1%
Not yet recruiting
426
12.0%
No approval data available
- AB Science received formal US patent approval (US12,472,164) for masitinib in treating sickle cell disease, providing intellectual property protection until November 2040. - Preclinical studies demonstrated masitinib's survival benefit in sickle cell disease mouse models, with 100% survival in treated mice compared to 83% mortality in controls within three hours. - The company is developing masitinib for severe forms of sickle cell disease representing approximately 65% of cases, targeting mast cell-mediated complications through a fully funded €9.2 million Phase 2 trial.
- AB Science has received a Notice of Allowance from the US Patent Office for masitinib in treating sickle cell disease, providing intellectual property protection until November 2040. - Masitinib uniquely targets mast cells in sickle cell disease treatment, showing promising preclinical results including complete prevention of vaso-occlusive crises and death in mouse models. - Clinical development is progressing through the SICKMAST program with €9.2 million funding, targeting both acute and chronic complications of sickle cell disease based on biomarker identification.
- A Phase 3 ARCADE trial demonstrates that combining irbesartan with celiprolol reduces severe arterial events by 50% in vascular Ehlers-Danlos syndrome patients over two years. - The study showed significant reduction in both symptomatic and asymptomatic arterial lesions, with patients on irbesartan experiencing fewer events (13) compared to placebo (35). - Irbesartan, an affordable generic medication, demonstrated a favorable safety profile with only minor adjustments needed for blood pressure management in some patients.
